Method and device of treating chronic kidney disease-associated pruritus
AssigneeAvior, Inc.
InventorNiraj Vasisht
Life of this patent
Estimating the term…
Abstract
The presently disclosed subject matter is directed to an effective method of treating chronic kidney disease-associated pruritus. Particularly, the method comprises the transmucosal administering of nalmefene to treat chronic kidney disease-associated pruritus, as well as cholestatic pruritus and/or prurigo nodularis. The nalmefene can be configured in a single layer film comprising at least two distinct domains. The film can include a first discrete domain comprising about 50-100 weight percent polymer matrix and the second discrete domain can comprise the nalmefene or pharmaceutically acceptable nalmefene salt.
Claims13
A method of treating pruritus in a subject, the method comprising transmucosally administering to a subject in need of such treatment a therapeutically effective amount of nalmefene or a pharmaceutically acceptable salt thereof,
- wherein the nalmefene or pharmaceutically acceptable nalmefene salt is administered through a single layer, self-supporting, mucoadhesive film, the film comprising:
- a first discrete domain and a second discrete domain;
- wherein the first discrete domain comprises 5 to 100 weight percent polymer matrix comprising hydroxy propyl methyl cellulose (HPMC) and sodium carboxymethyl cellulose (NaCMC) based on the total weight of the first discrete domain, and further comprises one or more of a permeation enhancer, and pH adjusting buffer,
- wherein the second discrete domain comprises nalmefene or a pharmaceutically acceptable nalmefene salt;
- wherein the second discrete domain is non-self-supporting;
- and
- wherein the local pH of the first discrete domain is in a range of 3.5 to 8.5, and the local pH of the second discrete domain is in a range of 4 to 9.
Dependencies are inferred from the claim text.